ALLMedicine™ Severe Acute Respiratory Syndrome Center
Research & Reviews 13,289 results
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8059477
Mediators of Inflammation; Ahmadi Badi S, Tarashi S et. al.
May 6th, 2021 - Severe acute respiratory syndrome-coronavirus 2 (SARS-CoV-2) is responsible for the outbreak of a new viral respiratory infection. It has been demonstrated that the microbiota has a crucial role in establishing immune responses against respiratory...
https://doi.org/10.1523/ENEURO.0027-21.2021
ENeuro Costa KCM, Brigante TAV et. al.
May 6th, 2021 - The Coronavirus Disease - 2019 (COVID-19) presents a variability of clinical symptoms, ranging from asymptomatic to severe respiratory and systemic conditions. In a cohort of patients, the Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV-2)...
https://doi.org/10.1177/09636897211010632
Cell Transplantation; Ye CH, Hsu WL et. al.
May 5th, 2021 - Severe acute respiratory syndrome coronavirus (SARS-CoV-2) first emerged in December 2019 in Wuhan, China, and has since spread rapidly worldwide. As researchers seek to learn more about COVID-19, the disease it causes, this novel virus continues ...
https://doi.org/10.1186/s12985-021-01567-3 10.1371/journal.pone.0048508 10.1371/journal.pone.0246903 10.1371/journal.pmed.1003346 10.3138/jammi-2020-0030 10.1016/j.jiph.2020.07.001 10.1093/ije/dyg054 10.1016/j.jinf.2020.10.017 10.1016/j.cca.2020.08.033 10.1101/2020.10.30.20215335 10.1016/S0140-6736(20)32635-0 10.1371/journal.pone.0236564 10.1093/ofid/ofv152 10.3390/diagnostics10080605 10.1016/j.jcv.2020.104579 10.1038/s41598-020-79985-6 10.1128/JCM.00721-20 10.1093/cid/ciaa882 10.1016/S2213-2600(20)30354-4 10.2147/IDR.S264020 10.1101/2020.06.11.20129072 10.1038/s41467-020-18611-5 10.1056/NEJMc2016321 10.1007/s10096-020-03972-y 10.1021/acs.analchem.0c01884 10.1016/j.jcv.2020.104417 10.1093/cid/ciaa345 10.1038/s41598-021-82765-5
Virology Journal; Kriegova E, Fillerova R et. al.
May 5th, 2021 - The early identification of asymptomatic yet infectious cases is vital to curb the 2019 coronavirus (COVID-19) pandemic and to control the disease in the post-pandemic era. In this paper, we propose a fast, inexpensive and high-throughput approach...
https://doi.org/10.1186/s12879-021-06108-5 10.1056/NEJMc2016359 10.3201/eid2611.203283 10.1128/JCM.01946-20 10.1016/S2666-5247(20)30120-8 10.1016/S0140-6736(20)32137-1 10.1016/j.immuni.2020.10.004 10.1056/NEJMc2025179
BMC Infectious Diseases; Caulley L, Shaw J et. al.
May 5th, 2021 - Salivary detection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has been proposed as an alternative to nasopharyngeal or oropharyngeal swab testing. Our group previously published a study demonstrating that both testing methods ...
Guidelines 249 results
https://doi.org/10.1097/ACO.0000000000001001
Current Opinion in Anaesthesiology; Bernstein K, Landau R
Apr 19th, 2021 - To describe updates to pragmatic recommendations that were published during the first coronavirus disease 2019 (COVID-19) surge, including the current thinking about whether pregnancy worsens the severity of COVID-19. Although a majority of pregna...
https://www.nejm.org/doi/full/10.1056/NEJMc2106075?query=featured_home
New England Journal of Medicine; Sadoff J, .
Apr 15th, 2021 - A case report by Muir et al.1 describes thrombosis, including cerebral venous sinus thrombosis (CVST), associated with severe thrombocytopenia and disseminated intravascular coagulation in a recipient of the Ad26.COV2.S vaccine (Johnson & Johnson/...
https://www.nejm.org/doi/full/10.1056/NEJMc2103825?query=featured_coronavirus
New England Journal of Medicine; Anichini G, .
Apr 12th, 2021 - Whether or not persons who have already been infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) should be vaccinated is unclear. Only a few studies have shown that vaccinees who were previously infected with SARS-CoV-2 had ...
https://www.nejm.org/doi/full/10.1056/NEJMc2101667
New England Journal of Medicine; Krammer F, Srivastava K et. al.
Apr 7th, 2021 - The efficacy of two injections of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike messenger RNA (mRNA) vaccines (BNT162b2 [Pfizer] and mRNA-1273 [Moderna])1 in preventing symptomatic SARS-CoV-2 infection in persons without p...
https://www.nejm.org/doi/full/10.1056/NEJMc2101927?query=recirc_mostViewed_railB_article
New England Journal of Medicine; Keehner J, Horton LE et. al.
Mar 22nd, 2021 - Data from phase 3 clinical trials of messenger RNA (mRNA) vaccines through November 2020 showed 94.1% efficacy for the prevention of symptomatic severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection at 14 days after the second dos...
Drugs 1 results see all →
Clinicaltrials.gov 13,653 results
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8059477
Mediators of Inflammation; Ahmadi Badi S, Tarashi S et. al.
May 6th, 2021 - Severe acute respiratory syndrome-coronavirus 2 (SARS-CoV-2) is responsible for the outbreak of a new viral respiratory infection. It has been demonstrated that the microbiota has a crucial role in establishing immune responses against respiratory...
https://doi.org/10.1523/ENEURO.0027-21.2021
ENeuro Costa KCM, Brigante TAV et. al.
May 6th, 2021 - The Coronavirus Disease - 2019 (COVID-19) presents a variability of clinical symptoms, ranging from asymptomatic to severe respiratory and systemic conditions. In a cohort of patients, the Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV-2)...
https://doi.org/10.1177/09636897211010632
Cell Transplantation; Ye CH, Hsu WL et. al.
May 5th, 2021 - Severe acute respiratory syndrome coronavirus (SARS-CoV-2) first emerged in December 2019 in Wuhan, China, and has since spread rapidly worldwide. As researchers seek to learn more about COVID-19, the disease it causes, this novel virus continues ...
https://doi.org/10.1186/s12985-021-01567-3 10.1371/journal.pone.0048508 10.1371/journal.pone.0246903 10.1371/journal.pmed.1003346 10.3138/jammi-2020-0030 10.1016/j.jiph.2020.07.001 10.1093/ije/dyg054 10.1016/j.jinf.2020.10.017 10.1016/j.cca.2020.08.033 10.1101/2020.10.30.20215335 10.1016/S0140-6736(20)32635-0 10.1371/journal.pone.0236564 10.1093/ofid/ofv152 10.3390/diagnostics10080605 10.1016/j.jcv.2020.104579 10.1038/s41598-020-79985-6 10.1128/JCM.00721-20 10.1093/cid/ciaa882 10.1016/S2213-2600(20)30354-4 10.2147/IDR.S264020 10.1101/2020.06.11.20129072 10.1038/s41467-020-18611-5 10.1056/NEJMc2016321 10.1007/s10096-020-03972-y 10.1021/acs.analchem.0c01884 10.1016/j.jcv.2020.104417 10.1093/cid/ciaa345 10.1038/s41598-021-82765-5
Virology Journal; Kriegova E, Fillerova R et. al.
May 5th, 2021 - The early identification of asymptomatic yet infectious cases is vital to curb the 2019 coronavirus (COVID-19) pandemic and to control the disease in the post-pandemic era. In this paper, we propose a fast, inexpensive and high-throughput approach...
https://doi.org/10.1186/s12879-021-06108-5 10.1056/NEJMc2016359 10.3201/eid2611.203283 10.1128/JCM.01946-20 10.1016/S2666-5247(20)30120-8 10.1016/S0140-6736(20)32137-1 10.1016/j.immuni.2020.10.004 10.1056/NEJMc2025179
BMC Infectious Diseases; Caulley L, Shaw J et. al.
May 5th, 2021 - Salivary detection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has been proposed as an alternative to nasopharyngeal or oropharyngeal swab testing. Our group previously published a study demonstrating that both testing methods ...
News 535 results
https://www.nejm.org/doi/full/10.1056/NEJMc2106075?query=featured_home
New England Journal of Medicine; Sadoff J, .
Apr 15th, 2021 - A case report by Muir et al.1 describes thrombosis, including cerebral venous sinus thrombosis (CVST), associated with severe thrombocytopenia and disseminated intravascular coagulation in a recipient of the Ad26.COV2.S vaccine (Johnson & Johnson/...
https://www.nejm.org/doi/full/10.1056/NEJMc2103825?query=featured_coronavirus
New England Journal of Medicine; Anichini G, .
Apr 12th, 2021 - Whether or not persons who have already been infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) should be vaccinated is unclear. Only a few studies have shown that vaccinees who were previously infected with SARS-CoV-2 had ...
https://www.nejm.org/doi/full/10.1056/NEJMc2101667
New England Journal of Medicine; Krammer F, Srivastava K et. al.
Apr 7th, 2021 - The efficacy of two injections of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike messenger RNA (mRNA) vaccines (BNT162b2 [Pfizer] and mRNA-1273 [Moderna])1 in preventing symptomatic SARS-CoV-2 infection in persons without p...
https://www.nejm.org/doi/full/10.1056/NEJMc2101927?query=recirc_mostViewed_railB_article
New England Journal of Medicine; Keehner J, Horton LE et. al.
Mar 22nd, 2021 - Data from phase 3 clinical trials of messenger RNA (mRNA) vaccines through November 2020 showed 94.1% efficacy for the prevention of symptomatic severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection at 14 days after the second dos...
https://www.nature.com/articles/s41591-021-01283-z
Nature Medicine; Nalbandian, A. et. al.
Mar 21st, 2021 - Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the pathogen responsible for the coronavirus disease 2019 (COVID-19) pandemic, which has resulted in global healthcare crises and strained health resources. As the population of patie...
